Given high rates of smoking among cancer patients, smoking cessation treatment is crucial;
yet limited data exist to guide integration of such trials into the oncologic context. In order to
determine the feasibility of conducting smoking cessation clinical trials with cancer patients,
screening and baseline data from a large randomized placebo-controlled pharmacotherapy
trial were analyzed. Descriptive statistics and regression analyses were used to compare
enrollees to decliners, describe program enrollees, and assess correlates of confidence in …